Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 75/100

Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

Key Takeaway: Co-Diagnostics, through its joint venture CoSara, is actively participating in regional conferences in India to strengthen its distributor relationships. The company is introducing its SARAGENE® diagnostic products and preparing for clinical studies related to the Co-Dx PCR Mycobacterium Tuberculosis Test. CoSara's involvement aligns with India's manufacturing initiative, showcasing its commitment to local production.
Price reaction · baseline $5.98 (2026-01-12 close) · hit pre-market · clean, no other CODX news in the window
day 0 close · peak
-60.5%
day 1
-44%
day 3
-52.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • CoSara is expanding its distributor base in India.
  • Participation in regional conferences enhances visibility and relationships.
  • Introduction of SARAGENE® products and Co-Dx™ PCR platform to new customers.
  • Alignment with the 'Make in India' initiative supports local manufacturing.

Full Press Release Details

SALT LAKE CITY,Jan. 12, 2026/PRNewswire/ --Co-Diagnostics, Inc.(Nasdaq: CODX)("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences.
The events provided opportunities for CoSara to introduce its SARAGENE® diagnostic products, as well as the upcoming Co-Dx™ PCR platform*, to new customers and to expand its existing base of over 40 distributors across the country.
The conferences come as CoSara prepares to assist in the clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test on the Co-Dx PCR platform. CoSara will also participate in manufacturing the PCR Pro™ instrument and MTB test cups to align with the "Make in India" initiative.
CoSara exhibited at the 44thGujarat Association of Pathologists & Microbiologists ("GAPM") conference in Gujarat which took place on January 10-11. The 13thAssociation of Clinical Laboratory Analysts & Practitioners ("ACLAP") in Maharashtra took place during the same time.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.
SOURCE Co-Diagnostics

Frequently Asked Questions

What is the purpose of CoSara's participation in conferences?

CoSara aims to strengthen distributor relationships and introduce its diagnostic products.

Which conferences did CoSara attend?

CoSara participated in the GAPM conference in Gujarat and the ACLAP conference in Maharashtra.

What products are being introduced by CoSara?

CoSara is introducing its SARAGENE® diagnostic products and the Co-Dx™ PCR platform.

How does CoSara align with the 'Make in India' initiative?

CoSara is involved in manufacturing the PCR Pro™ instrument and MTB test cups locally.

Last updated: Jan 13, 2026